Molecular misreading: The occurrence of frameshift proteins in different diseases by Leeuwen, F.W. (Fred) van et al.
738 Biochemical Society Transactions (2006) Volume 34, part 5
Molecular misreading: the occurrence of
frameshift proteins in different diseases1
F.W. van Leeuwen*2, J.M. Kros†, W. Kamphorst‡, C. van Schravendijk§ and R.A.I. de Vos‖
*Netherlands Institute for Neuroscience, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands, †Department of Pathology, Erasmus Medical Center,
Rotterdam, The Netherlands, ‡Department of Neuropathology, VU Medical Center, Amsterdam, The Netherlands, §Diabetes Research Center, Brussels Free
University-VUB, Brussels, Belgium, and ‖Laboratory for Neuropathology East Netherlands, Enschede, The Netherlands
Abstract
Neuronal homoeostasis requires a constant balance between biosynthetic and catabolic processes. Eukaryotic
cells primarily use two distinctmechanisms for degradation: the proteasome and autophagy of aggregates by
the lysosomes. We focused on the UPS (ubiquitin–proteasome system). As a result of molecular misreading,
misframed UBB (ubiquitin B) (UBB+1) is generated. UBB+1 accumulates in the neuritic plaques and neuro-
fibrillary tangles in all patients with AD (Alzheimer’s disease) and in the neuronal and glial hallmarks of
other tauopathies and in polyglutamine diseases such as Huntington’s disease. UBB+1 is not present in
synucleinopathies such as Parkinson’s disease. We showed that UBB+1 causes UPS dysfunction, aggregation
and apoptotic cell death. UBB+1 is also present in non-neurological cells, hepatocytes of the diseased
liver and in muscles during inclusion body myositis. Other frequently occurring (age-related) diseases such
as Type 2 (non-insulin-dependent) diabetes mellitus are currently under investigation. These findings point
to the importance of the UPS in diseases and open new avenues for target identification of the main players
of the UPS. Treatment of these diseases with tools (e.g. viral RNA interference constructs) to intervene with
specific targets is the next step.
Introduction
The discovery of molecular misreading
Molecular misreading of genes (i.e. the inaccurate conversion
of genomic information into aberrant proteins) was demon-
strated in the VP (vasopressin) gene ofmagnocellular neurons
in the hypothalamus of the homozygous Brattleboro mutant
rat [1]. The mutant trait (diabetes insipidus) is inherited in an
autosomal recessive way according to classic Mendelian gen-
etics. Gene cloning revealed the mutation: a single guanine
residue deletion in exon B results in a VP precursor protein
with a very sticky polylysine C-terminus which is arrested
in the endoplasmic reticulum. Consequently, VP is missing
from the posterior pituitary of these animals [2]. However,
surprisingly, solitary neurons were intensely stained with
antibodies against the normal C-terminus of the VP pre-
cursor. These neurons, with a revertant VP phenotype, were
shown to increase in number with advancing age due to the
diseased state of these animals.Analysis of themRNAof these
cells revealed dinucleotide deletions (GA) located down-
stream of the glycine deletion, in GAGAG motifs. Con-
sequently, at these points, the normal reading frame was re-
stored [3,4].
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Subsequently, the question was raised whether this mut-
ation is a peculiarity of the Brattleboro rat or a more general
phenomenon. The wild-type VP genes of rat and human
have the same GAGAG motifs. Indeed, antibodies directed
against the predicted VP sequences in the +1 reading frame
resulted in an intense staining of a number of magnocellular
neurons [4]. Thus a similar dinucleotide deletion (GA) is
likely to occur in wild-type sequences and is not restricted to
homozygous Brattleboro rats. It is important to realize that,
in these cases, an abnormalVPprecursor protein is createdout
of a normal one. These abnormal +1 proteins are potentially
functionally disturbed [1,3]. Molecular misreading also hap-
pens in non-neuronal cells, as was shown in transgenic VP
mouse lines having ectopic expression of VP [5].
Which transcripts have GAGAG motifs?
The next step was to see if other genes have GAGAG
motifs or other simple repeats. The chance of encountering
a GAGAG motif is 1:1024, and there are many genomic
sequences that have such a potentially error-prone site. In
the first instance, we focused on AD (Alzheimer’s disease)-
associated genes such as APP (amyloid precursor protein)
and UBB (ubiquitin B), of which indeed the respective +1
proteins were found as the hallmarks of all cases of AD
(including sporadic ones) andDown’s syndrome [6]. The pro-
posed dinucleotide deletions were found as well. The
existence of these dinucleotide deletions was confirmed inde-
pendently [7]. Several +1 proteins appeared to co-exist [e.g.
UBB+1, GFAP+1 (glial fibrillary acidic protein) and APP+1;
Figure 1A–1C respectively] due to molecular misreading
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Figure 1 Co-existence of various +1 proteins
Consecutive 6 µm thick paraffin sections of the hippocampus of a 70-year-old-patient suffering from AD showing co-existence
of UBB+1, GFAP+1 and APP+1 in a hallmark of AD, neurofibrillary tangles. Star symbols indicate capillaries for orientation.
Scale bar, 25 µm.
(APP and UBB) and exon skipping [8]. We subsequently
focused onUBB because of the potentially devastating effects
of both a gain or loss of function of the resulting +1 protein
in different cellular processes.
UBB and its mutant form: UBB+1
Ubiquitin is a multigene family (i.e. ubiquitins A, B and C),
with two polyubiquitin genes encoding multiple repeats of
ubiquitin [9,10]. The human UBB gene is localized on chro-
mosome 17p11.2. UBB is one of the best-conserved eukaryo-
tic proteins. From yeast to human, only at three positions
does the amino acid sequence show variation in the 76-
residue-long protein, indicating its functional relevance.UBB
is synthesized in a three repeat from which 76 amino acids
are cleaved. The UBB molecule harbours a number of lysine
moieties, of which numbers 29 and 48 are involved in ATP-
dependent polyubiquitination, a process that triggers trans-
port to the proteasome, followed by proteolysis. Ubiquitin
is not only implicated in protein degradation during disease
[11,12] but also in an array of other functions (e.g. in synaptic
function and plasticity) [13].
At the C-terminus of UBB, a glycine moiety (no. 76)
is present, which is essential for all biological functions of
UBB. A few nucleotides upstream of this C-terminal glycine
moiety, a GAGAGmotif is present (Figure 2). The result of a
dinucleotide deletion in this motif is a loss of the C-terminal
glycine moiety and a 19-amino-acids-longer ubiquitin mol-
ecule called ubiquitin+1 (UBB+1). It was shown that UBB+1
is unable to ubiquitinate, is a UFD (ubiquitin-fusion degrad-
ation) substrate for proteasomal degradation and inhibits pro-
teasomal degradation [14] in a dose-dependent way: low
levels of UBB+1 are degraded, whereas higher levels inhibit
the proteasome. In other words UBB+1 by itself is degraded
but if another cellular stressor (e.g. amyloid β-peptide) is
present, UBB+1 may become toxic. It was shown that ubi-
quitinated-UBB+1 chains are very refractory to disassembly
by de-ubiquitination and potentially inhibit proteasomal
degradation by purified 26 S proteasomes [15]. High express-
ion of UBB+1 proteins in neuroblastoma cells induces HSP
(heat-shock protein) expression (HSP40 and HSP70), resi-
stance to oxidative stress and apoptosis [16,17]. In vitro, it
was shown that UBB+1 enhances aggregation of polyglut-
amine proteins and synergistically aggravates polyglutamine-
induced cell death [18]. The ubiquitin-conjugating enzyme
[E2-25K/Hip2 (Huntingtin-interacting protein 2)] has been
functionally implicated in the mediation of amyloid β-pep-
tide neurotoxicity and proteasome inhibition by UBB+1
in vitro [19]. Furthermore, the presence of UBB+1 in histo-
logical sections is a marker for proteasome impairment in a
disease-specific manner in neuronal and glial cells (tauopath-
ies and polyglutamine diseases but not in synucleinopathies)
[20], and in non-neuronal cells (Figures 3A–3C) [21,22].
In order to assess if UBB+1 protein is functionally relevant
to neuronal functioning, we have generated transgenic mouse
lines expressing UBB+1 protein at low and high levels in the
brain (with the Ca2+/calmodulin-dependent protein kinase
IIα promoter). We noted UBB+1 accumulation in forebrain
regions (e.g. the hippocampus and cerebral cortex) in a high
UBB+1 expression line and a deficit in spatial memory,
indicating that optimal activity of the UPS (ubiquitin–
proteasome system) is required for cognitive function (D.F.
Fischer, P. van Tijn, B. Hobo and F.W. van Leeuwen,
unpublishedwork). Proteomic analyses of the cerebral cortex
of thesemice taught us differences in the expression pattern of
various compounds (e.g. those involved in energymetabolism
and in axonal transport) [22a–22c].
Other +1 proteins in diseases
APP+1
APP+1 was present in the cellular hallmarks from all tauo-
pathies but not in synucleinopathies [6,23]. APP+1 was found
to be a secretory protein. Unexpectedly, we found that the
APP+1 level in theCSF (cerebrospinal fluid) of non-demented
controls was much higher than that in the CSF of patients
suffering from AD. Also the level of APP+1 in CSF was
inversely correlated with the severity of neuropathology,
especially between Braak stages 0 and 1 [24]. These results
were confirmed in the transgenic APP+1 mouse [25]. If
accumulated, APP+1 can increase the levels of secreted Aβ40
(amyloid β-peptide 40) and contribute to AD pathology [26].
In conclusion, measuring levels of APP+1 in CSF can help in
diagnosing AD at an early stage.
GFAP+1
Overexpression of genes in the course of a disease has
been correlated to molecular misreading [1,6]. Along this
line, we reasoned that astrocyte proliferation and possibly
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Figure 2 Polyubiquitination of proteasome substrates
Simplified and schematic representation of how ubiquitin acts via polyubiquitination through a number of enzymatic steps
(E1, E2 and E3) (left panel; for details, see [39]). The lysine moieties (K) at positions 29 and 48 are involved in the
polyubiquitination and degradation. At the C-terminus of UBB, a GAGAG motif is present. It was shown that adjacent to this
motif a dinucleotide deletion (GU) occurs, resulting in an extension of 20 amino acids (right panel). Due to the dinucleotide
deletion, the Gly76 moiety at the C-terminus, essential for binding to a target protein, is not synthesized. Consequently, this
molecule cannot ubiquitinate. In fact, UBB+1 is the first naturally occurring UFD substrate identified [14]. Of much interest
is that it was recently suggested that E3 enzymes form a ‘forked’ polyubiquitin chain in which two ubiquitin chains are
linked to adjacent lysine residues on a preceding ubiquitin moiety (e.g. Lys29 and Lys48). The forked polyubiquitin chains ap-
peared to be relatively resistant to disassembly or degradation by the 26 S proteasomes (A.L. Goldberg and H.-T. Kim,
personal communication). It is thus possible that ubiquitinated UBB+1 is an inhibitor of the proteasome [15].
GFAP overexpression in AD may result in frameshift GFAP
(GFAP+1) in reactive astrocytes in AD. To our surprise, we
found GFAP+1 to be present predominantly in neurons (Fig-
ure 3D), suggesting a retrodifferentiation of these neurons
[8]. Subsequent analysis of GFAP transcripts revealed that
GFAP+1 immunoreactivity is due to novelGFAP splice forms
[8].
Proteasomal quality control mechanisms may be impaired
in neuroepithelial tumours of which the astrocytomas, in-
cluding glioblastomas, are the most frequent form (80%)
[27,28]. However, we did not find any UBB+1 immuno-
reactivity in these tumours. Low-grade astrocytomas are
usually associated with high GFAP expression. Indeed
GFAP+1 protein expression was found in some forms of
astrocytomas (in 12 out of 36 cases) but not in oligodendrog-
lioma (n= 6) or meningioma (n= 2), indicating a need to
further analyse these findings and to reveal a possible
functional relevance for GFAP+1 (Figure 3E) [29].
p53+1
Another interesting molecule is p53, known as the tumour-
suppressor gene. It contains two GAGAG motifs in exons 8
and 10 [30]. In the first one, present in the DNA-binding
region at amino acid residue 280, a dinucleotide deletion
(GA) results in p53+1 with a novel C-terminus of 24 amino
acids. p53+1 lacks the oligodimerization domain and nuclear
localization and export signals.Against the last 14 amino acids
(QERGASPRAAPREH) of p53+1, an antibody was raised
that resulted in an intense staining of the pyramidal cells of
the human hippocampus (F.W. van Leeuwen, unpublished
work). However, in neuroepithelial tumours tested so far,
no staining was obtained. The GAGAG motif in exon 10
(oligodimerization domain) resulted in an almost immediate
stop and was not considered.
Conclusions and future plans
(i) Frameshift proteins may contribute to cellular dysfunc-
tion in many diseases. UBB+1 has dual substrate/inhibitor ef-
fects on the proteasome. If UBB+1 accumulates, it causes pro-
teasomal dysfunction in various neuronal and non-neuronal
diseases.
(ii) Many forms of (age-related) diseases are sporadic and
multifactorial. Thismeans that in thenext years the generation
ofmoremultiple transgenic animals such as those forADmay
C©2006 Biochemical Society
Information Processing and Molecular Signalling 741
Figure 3 UBB+1 and GFAP+1 in various diseases
UBB+1 (A–C) and GFAP+1 (D, E) staining in 50 µm Vibratome (A, D) and 6 µm thick paraffin sections (B, C, E). In (A) and
(C) in the hippocampus of a 92-year-old patient suffering from AD, intense immunoreactivity can be seen in neurofibrillary
tangles. Disease-specific expression of UBB+1 has been found in tauopathies. However, in FTD (frontotemporal dementia),
UBB+1 is only present in three of eight examples, reflecting the heterogeneity in the clinical and pathological phenotypes
[20]. In synucleinopathies [LBD (Lewy body disease) and MSA (multiple system atrophy)], UBB+1 is absent [20]. Remarkably,
GFAP+1 accumulation was only detected in AD and in two of eight cases of Pick’s disease. In other tauopathies (progressive
supranuclear palsy, n= 5; FTD, n= 3; and argyrophylic grain disease, n= 5), in synucleinopathies (Parkinson’s disease/LBD,
n= 20; and MSA, n= 5) and in multiple sclerosis (n= 11), no GFAP+1 immunoreactivity was observed. In (B), UBB+1 staining
is present in Mallory bodies of the liver of a 53-year-old patient with alcohol abuse and liver cirrhosis (no. 7) [20]. Star
symbols in this Figure indicate lipid droplets. No staining was obtained with anti-APP+1 and anti-GFAP+1 antibodies in nine
patients with alcoholic liver disease and Mallory bodies [21]. In (C), UBB+1 staining is shown in the endocrine pancreas using
three different anti-UBB+1 antibodies [20]; heterogeneous staining of β-cells in the islets of Langerhans of a person aged
65 years with a history of hypertension (not a diabetes mellitus patient). Note also non-reactive islets located in between
(star symbol). In (E), GFAP+1 staining is present in cell bodies (inset) of astrocytes and fibres in the brainstem of a female
(aged 12 years) with a pilocytic astrocytoma type 1. With APP+1 and UBB+1 antisera, no staining was obtained. Scale bars,
25 µm (E) and 10 µm (inset).
be expected (see e.g. [31]). In these models, alterations in the
UPS genes may be considered as relevant contributors to
the disease phenotypes.
(iii) The presence of UBB+1 in affected neurons in AD,
other tauopathies and several polyglutamine diseases, but
not in synucleinopathies (Figures 1A and 3A), may be used
as a marker for proteasome insufficiency. However, it has
been reported that the proteasome is not only inhibited in
AD [32] and Huntington’s disease (sharing UBB+1 accumul-
ation) but also in Parkinson’s disease [33]. We surmise that
the mechanisms leading to proteasomal insufficiency are
different in these diseases. Whereas in Parkinson’s disease the
ubiquitination andde-ubiquitinationmachinerymay falter, in
AD UBB+1 inhibition of the proteasome may act at the cap,
potentially due to clogging of 19 S subunit(s) with substrates
such as ubiquitinated UBB+1 [15,20,34,35]. Indeed, genetic
data point to a role for ubiquitination enzymes in familial
Parkinson’s disease [Parkin and UCH L-1 (ubiquitin C-
terminal hydrolase L-1)] [36]. These differences may result in
specific UPS targets that can be corrected by viral tools. RNA
silencing techniques to neutralize UPS transcripts or viral
technology to compensate for their lack are the candidates for
therapy as has been shown in polyglutamine diseases such as
Huntington’s disease [37,38].
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